TwitterFacebook Instagram

TRENTON, N

TRENTON, N

TRENTON, N.J. (AP) - Drug giant Pfizer says it won't split into two publicly traded companies, despite pressure from investors frustrated by its lagging stock price, ending years of Wall Street speculation over its strategy and future.

The biggest U.S.-based drugmaker said Monday it believes it is best positioned to maximize shareholder value in its current form, but it reserves the right to split in the future if the situation changes.

For several years, the maker of viagra tablets and the pain treatment Lyrica has been under growing pressure from analysts and investors who argued that by splitting up, the resulting two companies might grow faster than one.

FILE - In this Monday, Nov. 23, 2015, file photo, a man enters Pfizer's world headquarters, in New York. Pfizer will not split into two publicly traded companies, a decision that, at least for now, ends Wall Street speculation over the drugmaker's future. The company believes it is best positioned to maximize shareholder value in its current best price viagra form, but said Monday, Sept. 26, 2016, that it's reserving the right to split in the future if the situation changes. (AP Photo/Mark Lennihan, File)

As a result, Pfizer has been reporting detailed financial results for each of its business segments, information that would be required by regulators for a split. Earlier this year, Pfizer promised a decision by the end of the year, but then it reorganized and renamed those segments - a sign a breakup was less likely.

Chances of the breakup began to fade even more over the summer, due in part to increasing viagra sales for key new drugs from Pfizer and rising prospects for its drugs under development.

Pfizer CEO Ian Read told analysts last month that the prospect of a split was not a "make-or-break decision" for the company. The company recently said it had spent $600 million on preparations for such a split.

"Given that Pfizer has been talking down expectations for a separation in recent months, we think the stock will only be down modestly on this news," Jeffries analyst Jeffrey Holford viagra reviews wrote to investors.

Shares of Pfizer Inc. fell 70 cents, or 2 percent, to $33.56 in afternoon trading Monday. The stock is up about 5.4 percent over the past year.

Pfizer said Monday that a split would not help the competitive positioning of its businesses, and such a move would create disruptions and increased costs.

The drugmaker's most likely path forward involves hunting for more acquisition targets, according to Bernstein analyst Dr. Tim Anderson, who had pressed Pfizer repeatedly on its quarterly results conference calls to break up.

Pfizer has been buying several companies and products to help make up for a wave of sales losses to cheaper, buy generic viagra competition, most notably for the cholesterol pill Lipitor. It also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca Plc in 2014 and this year of Ireland's Allergan Plc.

Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from New York - but just on paper - to a country with lower tax rates to reduce its U.S. tax bill. AstraZeneca rebuffed Pfizer, and the U.S. Treasury Department set up new rules that effectively blocked the Allergan acquisition.

Last month, Pfizer said it would spend about $14 billion to buy generic viagra cancer drug developer Medivation, and it is buying rights to AstraZeneca's portfolio of approved and experimental antibiotic and antifungal pills. In June, Pfizer completed a $5.2-billion acquisition of Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

"A critic could argue that Pfizer is back to being the same old Pfizer as before, relying on (mergers and acquisitions) to grow and to refill its pipeline, but at the expense of growing larger in the process depending on the size of deals it chases," Anderson said in a research note.

___

AP Health Writer Tom Murphy contributed to this report from Indianapolis.

___

Follow Linda A. Johnson at website Pfizer decides not to break up business

For those who have any kind of inquiries about where by in addition to how to make use of best price viagra, you possibly can e mail us from the web page.

© Copyright 2015 by ZEKERİYA ÜNLÜ | Ünlü Müzik 
    Powered by Design Editing Grafikim.com & Yasin Akıllı

  TEL: +90 541 454 63 63 | AVRUPA MENEJERLİK 0049 173 5411536 | EMAIL: iletisim@zekeriyaunlu.com

seslendirme, dublaj, seslendirme yapmak, seslendirme kursu, voice, turkish voice, voice over, voice-over, perfore, dj, yapımcı, director, ses, ses kastı, kast, voice casting, casting, medya, turkish media, prodüksiyon, seslendirme sanatçısı, radyo, anahtar, gercek hayat, voice artist, dubbing, turkish voice talent, radio dictionary, seslendirmen, yasin erçağlayan, ercaglayan, 24 haber,tgrt, tvnet, haber programı, seslendirme sanatçısı, erçağlayan, profesyonel seslendirme, özel program sunumu, voice over master, belgesel reklam seslendirme, haber spikeri, kurumsal tanıtım filmi, reklam filmi, seslendirmesi, ana haber, yapımcı, sunucu, Haber 24,TGRT, TV8, KANAL 6, BTV AVRUPA, POWER FM, POWER TURK, POWER XL, INTERPRESS, TV NET yasinercaglayan, www.yasinercaglayan.com, reklam ses, erkek ses, bayan ses, reklam seslendirme, Seslendirme & Production Hizmetleri, gercek ses, poll ses, komik ses, edit, film, tanitim, radyo, tv reklam, Radio Jingles, oyuncu, oyuncular, diziler, aktor, kayit, reklam, filmi, ilk sesli, SESLENDIRME, sanatci, SANATCI, sanatcilar, sanatcisi, turk, turkiye, mikrofon, castajans, dizi, cast, ajans, yonetmen, sinema, Tv, dvd, CD, kurs, tiyatro, trt, miks, mix, kanal, senkron, televizyon, konusma, diksiyon, Diksiyon Diksiyon Dersi, Diksiyon Sanati, Guzel Konusma, Film Seslendirme, Seslendirme Sanati, Spikerlik, Vurgu Tonlama, Duzgun Konusma, Berrak Ses, Boguk Ses, Radyoculuk, Radyo Televizyon Konusma, kitap Seslendirme, Nefes Kontrolu, Diyafram Dis, dışses, dışses, Dik Seszantasyon, Sunum, Etkili, ve, Basarili, Konusma, Mix